Nutrition 21 Revenue and Competitors

Nutrition 21 is pioneering an effort to use patented technology, pharmaceutical research and strategic marketing and distribution partnerships to build its position in therapeutic markets. The Company is targeting the diabetes marketplace and related health markets where poor insulin function is a metabolic risk factor. These include obesity, metabolic syndrome, cardiovascular disease and depression. Poor insulin function and glucose control are strong bio-markers for diabetes. Chromium is a trace mineral essential for healthy insulin function and blood sugar levels. The Company holds 22 patents for chromium compounds, their uses and Chromax chromium picolinate, a unique form of chromium with superior bioactivity. Twelve (12) published clinical studies involving over 1500 subjects demonstrate that supplemental use of Chromax chromium picolinate, at 200 to 1000 mcg has demonstrated an ability to improve glycemic control in people with or at risk for diabetes.